It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The majority of patients with systemic lupus erythematosus (SLE) have high expression of type I IFN-stimulated genes. Mitochondrial abnormalities have also been reported, but the contribution of type I IFN exposure to these changes is unknown. Here, we show downregulation of mitochondria-derived genes and mitochondria-associated metabolic pathways in IFN-High patients from transcriptomic analysis of CD4+ and CD8+ T cells. CD8+ T cells from these patients have enlarged mitochondria and lower spare respiratory capacity associated with increased cell death upon rechallenge with TCR stimulation. These mitochondrial abnormalities can be phenocopied by exposing CD8+ T cells from healthy volunteers to type I IFN and TCR stimulation. Mechanistically these ‘SLE-like’ conditions increase CD8+ T cell NAD+ consumption resulting in impaired mitochondrial respiration and reduced cell viability, both of which can be rectified by NAD+ supplementation. Our data suggest that type I IFN exposure contributes to SLE pathogenesis by promoting CD8+ T cell death via metabolic rewiring.
Lupus pathogenesis is associated with high type 1 interferon stimulated gene (ISG) expression. Here, the authors correlate ISG expression in CD8+ T cells from lupus nephritis patients with abnormal mitochondrial function, implicating increased NAD consumption and reduced cell viability in the pathogenesis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Imperial College London, Department of Immunology and Inflammation, Centre for Inflammatory Disease, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
2 Imperial College London, MRC London Institute of Medical Sciences, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
3 Imperial College London, Department of Immunology and Inflammation, Centre for Inflammatory Disease, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College Healthcare NHS Trust, Imperial Lupus Centre, London, UK (GRID:grid.417895.6) (ISNI:0000 0001 0693 2181)
4 Imperial College Healthcare NHS Trust, Imperial Lupus Centre, London, UK (GRID:grid.417895.6) (ISNI:0000 0001 0693 2181)
5 Imperial College London, Department of Immunology and Inflammation, Centre for Inflammatory Disease, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); The University of Hong Kong, School of Biomedical Sciences, LKS Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757)